Recently, China Biotechnology Development Center released the Evaluation and Analysis Report on the Development Competitiveness of 2022 China Biomedical Industrial Parks at the 2022 China Biotechnology Innovation Conference, and the "2021 China Biomedical Park Development Competitiveness Ranking List" was announced simultaneously. Among them, Chengdu Hi tech Industrial Development Zone ranked third in the comprehensive competitiveness ranking of the park, up one place from the previous year, and firmly ranked the first echelon of national biomedical parks. In recent years, the bio pharmaceutical industry in Chengdu Hi tech Zone has developed vigorously, gathering more than 3000 pharmaceutical enterprises such as Sanofi and Medtronic. Accelerate the building of Chengdu Tianfu International Biological City and other key project clusters to help the gathering and development of the biomedical industry as the main position of Chengdu's industrial development. Chengdu Hi tech Zone closely focuses on building a circle and strengthening the chain, gives full play to the effectiveness of fund investment, and constantly optimizes and strengthens the biomedical industry. Up to now, Chengdu High tech Zone has guided the establishment of five medical and health sub funds, with a total fund size of 6.6 billion yuan. This year, more than 10 enterprises have been successfully launched through fund investment promotion. On October 27, the General Electric (GE) Medical China Precision Medical Industrialization Base project was signed and implemented, becoming the first industrialization base in Sichuan Province to be built by the multinational top 500 medical enterprises and the first industrialization project of GE Medical in western China. The cooperation between Chengdu Hi tech Zone and GE Healthcare is a powerful practice of Chengdu Hi tech Zone in promoting the construction of Chengdu Chongqing Double City Economic Circle and the construction of the Western (Chengdu) Science City. It is also a vivid embodiment of grasping the chain of main projects and promoting high-quality economic development. It will play a more exemplary and leading role in attracting high-level projects. At present, Chengdu Hi tech Zone is speeding up the construction of project clusters in key biomedical industry areas such as Chengdu Tianfu International Bio City and Frontier Medical Center, fostering new growth points and new competitive advantages. Chengdu Tianfu International Biological City is jointly built by Chengdu Hi tech Zone and Shuangliu District. Up to now, 200 projects have been introduced with a total investment of 120 billion yuan. Biotown aims to realize the innovation strategy source from 0 to 1, the achievement transformation from 1 to 10 through the scientific and technological innovation project cluster, and the industrial development from 10 to N through the manufacturing industry development project cluster, so as to achieve a good situation of the cluster development of the biomedical industry. Frontier Medical Center is located in Xinchuan Innovation Science Park of Chengdu High tech Zone. More than 60 high-quality projects, such as Beite Pharmaceutical R&D Center, have been settled and operated. It has gathered 2 academician level experts, 8 national level talents, 37 senior experts, and nearly 2000 research and development personnel. The National Precision Medicine Industry Innovation Center will be officially put into operation soon, becoming the third national innovation platform in the park. The key to building a full chain and full cycle industrial service system and continuously improving the innovation policy source of the bio industry is that Chengdu Hi tech Zone can steadily rank the first in the ranking list of the competitiveness of China's bio pharmaceutical parks, which lies in the innovation policy source capacity of Chengdu Hi tech Zone's achievements transformation, as well as the full chain and full cycle industrial service system provided for bio pharmaceutical enterprises. In May this year, Chengdu Hi tech Zone released 10 policies on building a circle and strengthening the chain development of the pharmaceutical and health industry, including strengthening the industrial chain, cultivating the innovation chain, stabilizing the supply chain, and configuring elements